1-boc-6-iodo-1,2,3,4-tetrahydroquinoline | 261732-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-boc-6-iodo-1,2,3,4-tetrahydroquinoline
• 英文别名: tert-butyl 6-iodo-3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 261732-44-9
• 化学式: C₁₄H₁₈INO₂
• 分子量: 359.207
• InChiKey: BXECCIBIWFTDJF-UHFFFAOYSA-N

物化性质

• 沸点：
  400.1±44.0 °C(Predicted)
• 密度：
  1.518±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-boc-6-iodo-1,2,3,4-tetrahydroquinoline 生成 ethyl 3-(1-boc-1,2,3,4-tetrahydro-quinolin-6-yl)crotonate
  参考文献：
  名称：

  Aza-bicycles which modulate the inhibition of cell adhesion

  摘要：

  该发明涉及式(I)的生理活性化合物，其中R1代表R3—Z3—，R3—L2—R4—Z3—，R3—L3—Ar1—L4—Z3—或R3—L3—Ar1—L2—R4—Z3—；R2代表氢，卤素，低烷基或低烷氧基；A1代表直链C1-3烷基链，可选择地被来自烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、亚胺、氧代、硫代或被—ZR6、—NY1Y2、—CO2R6或—C(═O)—NY1Y2取代的一个或多个基团取代；L1代表直接键；一种烯烃亚烷基链、烷基链、炔烃亚烷基链、环烯烃亚烷基链、环烷基链、杂芳基二亚基链、杂环烷基链或芳基链，每种链可选择地被(a)酸性官能团、氰基、氧代、—S(O)mR9、R3、—C(═O)—R3、—C(═O)—OR3、—N(R8)—C(═O)R9、—N(R8)—SO2—R9、—NY4Y5或—[C(═O)—N(R10)—C(R5)(R11)]p—C(═O)—NY4Y5取代，或者被(b)酸性官能团取代的烷基，或S(O)mR9、—C(═O)—NY4Y5或—NY4Y5；一种—[C(═O)—N(R10)—C(R5)(R11)]p—链；一种—Z2—R12—链；一种—C(═O)—CH2—C(═O)—链；一种—R12—Z2—R12—链；一种—C(R4)(R13)—[C(═O)—N(R10)—C(R5)(R11)]p—链；或一种—L5—L6—L7—链；Z1为C(R7)(R7a)、C(═O)或CH(OH)；Y为羧基或酸生物同位素；以及相应的N-氧化物及其前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂。这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4(&agr;4&bgr;1)相互作用的能力。

  公开号：

  US06608084B1
• 作为产物：
  描述：

  1-叔丁氧羰基6-溴-3,4-二氢-2H-喹啉 在 copper(l) iodide 、 sodium iodide 作用下， 以 1,4-二氧六环 为溶剂， 以96 %的产率得到1-boc-6-iodo-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Simplifying Access to Targeted Protein Degraders via Nickel Electrocatalytic Cross‐Coupling

  摘要：

  C−C linked glutarimide‐containing structures with direct utility in the preparation of cereblon‐based degraders (PROTACs, CELMoDs) can be assessed in a single step from inexpensive, commercial α‐bromoglutarimide through a unique Brønsted‐acid assisted Ni‐electrocatalytic approach. The reaction tolerates a broad array of functional groups that are historically problematic and can be applied to the simplified synthesis of dozens of known compounds that have only been procured through laborious, wasteful, multi‐step sequences. The reaction is scalable in both batch and flow and features a trivial procedure wherein the most time‐consuming aspect of reaction setup is weighing out the starting materials.

  DOI：

  10.1002/anie.202319856

文献信息

• AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION
  申请人：Aventis Pharma Limited

  公开号：EP1114028A1

  公开（公告）日：2001-07-11
• US6608084B1
  申请人：——

  公开号：US6608084B1

  公开（公告）日：2003-08-19
• [EN] AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION<br/>[FR] BICYCLES AZA MODULANT L'INHIBITION DE L'ADHESION CELLULAIRE
  申请人：RHONE POULENC RORER LTD

  公开号：WO2000015612A1

  公开（公告）日：2000-03-23

  The invention is directed to physiologically active compounds of formula (I) wherein R1 represents R?3-Z3-, R3-L2-R4-Z3-, R3-L3-Ar1-L4-Z3- or R3-L3-Ar1-L2-R4-Z3-; R2¿ represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C¿1-3?alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by -ZR?6, -NY1Y2, -CO¿2R6 or -C(=O)-NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, -S(O)¿mR?9, R3, -C(=O)-R3, -C(=O)-OR?3, -N(R8¿)-C(=O)-R?9, -N(R8¿)-C(=O)-OR?9, -N(R8)-SO¿2-R?9, -NY4Y5¿ or -[C(=O)-N(R?10)-C(R5)(R11)]¿p-C(=O)-NY4Y5, or by (b) alkyl substituted by an acidic functional group, or by S(O)¿mR?9, -C(=O)-NY?4Y5 or -NY4Y5¿; a -[C(=O)-N(R?10)-C(R5)(R11)]¿p- linkage; a -Z2-R12- linkage; a -C(=O)-CH¿2?-C(=O)- linkage; a -R?12-Z2-R12¿- linkage; a -C(R4)(R13)-[C(=O)-N(R?10)-C(R5)(R11)]¿p- linkage; or a -L5-L6-L7- linkage; Z?1 is C(R7)(R7a¿), C(=O) or CH(OH); Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).